PearlstoneNCT07827599
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Minor Trial sites expanded: 8 → 20 locations
- Notable Recruitment opened
- Trial sites expanded: 0 → 8 locations
- Start date changed from estimate of Sep 22, 2026 to Oct 16, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of Participants who are Infected With Influenza Virus (Reverse Transcription - Polymerase Chain Reaction [RT-PCR] Positive), and Present With Fever and at Least one Respiratory Symptom
Timeframe: From Day 1 up to Day 10
Secondary (3)
Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive), and Present With Fever or at Least one Influenza Symptom (Respiratory or Systemic)
Percentage of Participants who are Infected With Influenza Virus (RT-PCR Positive) Regardless of Body Temperature or Influenza Symptoms
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Arms and interventions
Baloxavir MarboxilExperimental
HHCs will receive baloxavir marboxil according to their body weight as outlined in the protocol.
PlaceboPlacebo comparator
HHCs will receive baloxavir marboxil matching placebo according to their body weight as outlined in the protocol.
No InterventionNo intervention
Index participants will not receive any study treatment but will continue to receive SOC treatment for influenza, as per the local guidelines.
Drugs: Baloxavir marboxil, Placebo
Sites
20 sites in 1 country